Evidence map›Paper›PMID 36155891›Full record

ArticlePharmacoEconomics - open2022

Healthcare Costs Among Patients with Psoriasis Treated with Ixekizumab Versus Secukinumab in Real-World Settings Over 24 Months.

Andrew Blauvelt, Nianwen Shi, Russel Burge, Bilal Atiya, Baojin Zhu, Najwa Somani, Terri Ridenour, Carolyn R Lew, Nicole M Zimmerman, Mwangi J Murage

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PharmacoEconomics - open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.1field-weighted citation impact, top 59% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 1 citations in OpenAlex.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Andrew BlauveltOregon Medical Research Center, Portland, OR, USA.
Nianwen ShiIBM Watson Health, Cambridge, MA, USA.
Russel BurgeValue, Evidence, and Outcomes (VEO), Eli Lilly and Company, LCT-South Building 171-2, Drop Code 5221, 1555 Harding St., Indianapolis, IN, 46221, USA.
Bilal AtiyaValue, Evidence, and Outcomes (VEO), Eli Lilly and Company, LCT-South Building 171-2, Drop Code 5221, 1555 Harding St., Indianapolis, IN, 46221, USA.
Baojin ZhuValue, Evidence, and Outcomes (VEO), Eli Lilly and Company, LCT-South Building 171-2, Drop Code 5221, 1555 Harding St., Indianapolis, IN, 46221, USA.
Najwa SomaniValue, Evidence, and Outcomes (VEO), Eli Lilly and Company, LCT-South Building 171-2, Drop Code 5221, 1555 Harding St., Indianapolis, IN, 46221, USA.
Terri RidenourValue, Evidence, and Outcomes (VEO), Eli Lilly and Company, LCT-South Building 171-2, Drop Code 5221, 1555 Harding St., Indianapolis, IN, 46221, USA.
Carolyn R LewIBM Watson Health, Cambridge, MA, USA.
Nicole M ZimmermanIBM Watson Health, Cambridge, MA, USA.
Mwangi J MurageValue, Evidence, and Outcomes (VEO), Eli Lilly and Company, LCT-South Building 171-2, Drop Code 5221, 1555 Harding St., Indianapolis, IN, 46221, USA. murage_mwangi_james@lilly.com.
Eli Lilly (United States) · USIBM (United States) · USOregon Medical Research Center · USUniversity of Cincinnati · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe aim of this study was to compare healthcare costs between ixekizumab (IXE)-treated and secukinumab (SEC)-treated patients with psoriasis over a 24-month follow-up period in the United States.

methodsPatients with psoriasis diagnosis were identified from IBM Watson Health MarketScan

resultsOverall, 1461 patients (IXE users, n = 471; SEC users, n = 990) were included. IXE versus SEC users had higher weighted PPPM all-cause, psoriasis-related, and index drug costs (p ≤ 0.001). IXE versus SEC users had comparable ICER-adjusted mean PPPM all-cause costs (US$4172 ± 3349 vs US$3978 ± 2619; p = 0.227) and psoriasis-related costs (US$2950 ± 1332 vs US$2899 ± 1152; p = 0.447). After applying ICER and adherence adjustments, index drug costs were similar between IXE and SEC users (US$3794 ± 1822 vs US$3766 ± 1973; p = 0.795).

conclusionsAll-cause and psoriasis-related costs were comparable between IXE and SEC users after ICER adjustments; index drug costs were similar after ICER and adherence adjustments.

Identifiers

PMID36155891
PMCPMC9596621
OpenAlexW4297229131

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.